Phage therapy: an alternative treatment modality for MDR bacterial infections
Infectious Diseases,
Год журнала:
2024,
Номер
56(10), С. 785 - 817
Опубликована: Июль 17, 2024
The
increasing
global
incidence
of
multidrug-resistant
(MDR)
bacterial
infections
threatens
public
health
and
compromises
various
aspects
modern
medicine.
Recognising
the
urgency
this
issue,
World
Health
Organisation
has
prioritised
development
novel
antimicrobials
to
combat
ESKAPEE
pathogens.
Comprising
Язык: Английский
Comprehensive Approaches to Combatting Acinetobacter baumannii Biofilms: From Biofilm Structure to Phage-Based Therapies
Antibiotics,
Год журнала:
2024,
Номер
13(11), С. 1064 - 1064
Опубликована: Ноя. 8, 2024
Acinetobacter
baumannii—a
multidrug-resistant
(MDR)
pathogen
that
causes,
for
example,
skin
and
soft
tissue
wounds;
urinary
tract
infections;
pneumonia;
bacteremia;
endocarditis,
particularly
due
to
its
ability
form
robust
biofilms—poses
a
significant
challenge
in
clinical
settings.
This
structure
protects
the
bacteria
from
immune
responses
antibiotic
treatments,
making
infections
difficult
eradicate.
Given
rise
resistance,
alternative
therapeutic
approaches
are
urgently
needed.
Bacteriophage-based
strategies
have
emerged
as
promising
solution
combating
A.
baumannii
biofilms.
Phages,
which
viruses
specifically
infect
bacteria,
offer
targeted
effective
means
of
disrupting
biofilm
lysing
bacterial
cells.
review
explores
current
advancements
bacteriophage
therapy,
focusing
on
potential
treating
biofilm-related
infections.
We
described
mechanisms
by
phages
interact
with
biofilms,
challenges
phage
therapy
implementation,
being
developed
enhance
efficacy
(phage
cocktails,
engineered
phages,
combination
therapies
antibiotics).
Understanding
role
bacteriophages
both
disruption
inhibition
forming
could
pave
way
innovative
treatments
MDR
well
prevention
their
development.
Язык: Английский
Mycobacteriophages in diagnosis and alternative treatment of mycobacterial infections
Frontiers in Microbiology,
Год журнала:
2023,
Номер
14
Опубликована: Сен. 28, 2023
Antimicrobial
resistance
is
an
increasing
threat
to
human
populations.
The
emergence
of
multidrug-resistant
“superbugs”
in
mycobacterial
infections
has
further
complicated
the
processes
curing
patients,
thereby
resulting
high
morbidity
and
mortality.
Early
diagnosis
alternative
treatment
are
important
for
improving
success
cure
rates
associated
with
use
mycobacteriophages
a
potentially
good
option.
Since
each
bacteriophage
its
own
host
range,
have
capacity
detect
specific
isolates.
bacteriolysis
properties
make
them
more
attractive
when
it
comes
treating
infectious
diseases.
In
fact,
they
been
clinically
applied
Eastern
Europe
several
decades.
Therefore,
can
also
treat
mycobacteria
infections.
This
review
explores
potential
clinical
applications
mycobacteriophages,
including
phage-based
phage
therapy
Furthermore,
this
summarizes
current
difficulties
therapy,
providing
insights
into
new
strategies
against
drug-resistant
mycobacteria.
Язык: Английский
Recent insights on phage therapy against multidrug-resistant Acinetobacter baumannii
AMB Express,
Год журнала:
2025,
Номер
15(1)
Опубликована: Март 12, 2025
Abstract
Acinetobacter
baumannii
is
a
prevalent
clinical
pathogen
commonly
found
to
be
multidrug-resistant
(MDR),
causing
serious
life-threatening
infections,
particularly
hospital-acquired
infections
with
limited
therapeutic
options.
The
MDR
phenotype
developed
against
this
critical
increasingly
globally,
reaching
pan-drug-resistant
conferring
non-susceptibility
all
antimicrobials
used
in
its
treatment
according
the
standard
guidelines.
Therefore,
it
develop
innovative
approaches,
such
as
phage
therapy,
considering
rise
drug-resistant
A.
infections.
In
review,
we
highlight
and
discuss
up-to-date
antimicrobial
resistance
of
,
use
phages,
their
limitations,
future
perspectives
treating
addition,
combination
phages
antimicrobials,
preclinical
studies
including
pharmacokinetics
pharmacodynamics
properties
have
been
discussed.
Язык: Английский
Bactericidal synergism between phage and antibiotics: A combination strategy to target multidrug-resistant Klebsiella pneumoniae in vitro and in vivo
European Journal of Pharmaceutics and Biopharmaceutics,
Год журнала:
2025,
Номер
213, С. 114759 - 114759
Опубликована: Май 28, 2025
Язык: Английский
Cell-free supernatant-assisted biogenic silver nanoparticles enhance the antibacterial efficacy of communicating bacterial pathogens
Biotechnology and Bioprocess Engineering,
Год журнала:
2024,
Номер
29(5), С. 902 - 914
Опубликована: Июнь 21, 2024
Язык: Английский
The treatment of Enterococcus faecalis related root canal biofilms with phage therapy
Microbial Pathogenesis,
Год журнала:
2024,
Номер
197, С. 107081 - 107081
Опубликована: Окт. 23, 2024
Язык: Английский
How to treat severe Acinetobacter baumannii infections
Current Opinion in Infectious Diseases,
Год журнала:
2023,
Номер
36(6), С. 596 - 608
Опубликована: Сен. 26, 2023
Purpose
of
review
To
update
the
management
severe
Acinetobacter
baumannii
infections
(ABI),
particularly
those
caused
by
multi-resistant
isolates.
Recent
findings
The
in
vitro
activity
various
antimicrobial
agents
potentially
helpful
treating
ABI
is
highly
variable
and
has
progressively
decreased
for
many
them,
limiting
current
therapeutic
options.
combination
more
than
one
drug
still
advisable
most
circumstances.
Ideally,
two
active
first-line
drugs
should
be
used.
Alternatively,
a
second-line
and,
if
this
not
possible,
or
combination.
emergence
new
such
as
Cefiderocol,
Sulbactam
Durlobactam,
Tetracyclines
offer
options
that
need
to
supported
clinical
evidence.
Summary
apparent
limitations
bacterium,
rapid
development
resistance,
serious
underlying
situation
cases
invite
search
alternatives
antibiotic
treatment,
promising
which
seems
bacteriophage
therapy.
Язык: Английский